Navigation Links
Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General
Date:10/10/2008

WALTHAM, Mass., Oct. 10 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (Amex: IMA), a leading provider of near-patient diagnostics, monitoring and health management solutions, met yesterday with Ban Ki-moon, the Secretary-General of the United Nations, as part of a group of senior executives of seventeen of the world's leading research-based and generic pharmaceutical and diagnostic companies. Inverness, together with senior officials from the United Nations system and representatives from the other firms, reviewed progress of programs to expand access to HIV prevention, treatment, care and support services in low and middle-income countries.

In connection with the meeting, Inverness provided information on its previously announced 4th generation rapid HIV diagnostic test, the Determine HIV-1/2 Ag/Ab Combo and disclosed publicly for the first time details on its unique Point-of-Care Analyzer upon which a first of its kind CD4 cell enumeration test will be deployed.

For individuals who have been confirmed as being HIV positive, testing for CD4, or T helper cells, is a critical baseline measurement to gauge the state of their immune system and for clinicians to initiate antiretroviral (ART) HIV therapy. It indicates how far the disease has advanced and the risk to the patient of complications or debilitating infections. CD4 is also measured at regular intervals during course of HIV therapy.

The Inverness CD4 system has been designed for use in point of care settings in the developing world, as well as in hospitals and in physician's offices in the developed world and potentially in the home as part of an enhanced health management program. It is a simple to operate, portable system with a rechargeable battery and provides rapid results in 15 minutes or less. Using a small finger stick blood sample, the platform may be able to deliver not only CD4 cell enumeration but ultimately provide diagnostic capabilities for a wide array of additional markers.

It is estimated that less then 1/3 of those confirmed as being HIV positive in the developing world have access to this critical information and the Inverness CD4 instrument will be the first device to enable low cost CD4 quantification at these point-of-care settings, where the need is greatest.

Clinical trials for the CD4 system will begin in the 4th quarter of this year and the instrument will be launched to select markets in mid-2009. Inverness plans to feature the product at the 15th Annual Conference on AIDS and STIs (ICASA) in Dakar, Senegal December 3-7, 2008.

Ron Zwanziger, President and CEO Inverness Medical Innovations, stated, "We are very pleased with the development progress of the analyzer platform and the broad possibilities for its application across our disease management portfolio. We also realize the immediate significant impact it will have upon the care of those living with HIV in the developing world where few technologies are available at point-of-care."

The Inverness CD4 point-of-care analyzer reflects the commitment by Inverness Medical Innovations to develop and bring to market innovative diagnostics to identify infectious disease and to enable effective health management of those with chronic conditions.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

For more information about Inverness Medical Innovations, please visit our website at http://www.invernessmedical.com.

This press release may contain forward-looking statements within the meaning of the federal securities laws, including statements regarding timing of the product release and benefits of the new product. These statements reflect Inverness' current views with respect to future events and are based on its management's current assumptions and information currently available. Actual results may differ materially due to numerous factors including, without limitation, risks associated with Inverness' ability to complete clinical trials of the product within the time frame suggested and with results that support the anticipated performance of the new product; Inverness ability to secure and maintain the regulatory approvals or clearances necessary to sell the product in various markets; market acceptance of the product; Inverness' ability to successfully manufacture and distribute the product; and the risks and uncertainties described in Inverness' annual report on Form 10-K, and other factors identified from time to time in its periodic filings with the Securities and Exchange Commission. Inverness undertakes no obligation to update any forward-looking statements contained herein.


'/>"/>
SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Inverness Medical Innovations Receives USDA Licensure of the BinaxNOW(R) Avian Influenza Virus Type A Antigen Test Kit
2. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
3. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
4. TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
5. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
6. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
7. Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children
8. Resurgent Health and Medical Announces That Childrens Hospitals and Clinics of Minnesota has Ordered 25 CleanTech Automated Handwashing Systems
9. International Medical Corps Matched with Top 25 American Express Members Project, Saving the Lives of Malnourished Children
10. Concentric Medical to Sponsor Randomized Trial
11. MedNet Solutions to Sponsor and Exhibit at the 2008 Advanced Medical Technology Association Conference in Washington, D.C.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the ... New Orleans. This is a new, greatly improved version of the Doctor Referral teaming ... requests by Fred Trotter and subsequently called the the “Doctor Referral Dataset” as released ...
(Date:6/24/2017)... (PRWEB) , ... June 24, 2017 , ... ... Dental365 family. Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients ... and weekends so that visits to the dentist fit into their patients’ busy ...
(Date:6/23/2017)... ... June 23, 2017 , ... By scoring 100% for fiscal ... four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's work as a ... all charities reviewed by Charity Navigator and earns ANRF a spot on their “ ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection ... denied entry to the JFK Virgin Atlantic lounge. , Bensko is no stranger ... six years ago, Bensko dedicated her life to supporting our wounded veterans. A world-class ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... Breast Cancer Conference from Sept. 18 to 20. , The two-day conference is ... subtype with the goal of improving patients’ lives and eliminating racial breast cancer-related ...
Breaking Medicine News(10 mins):